Euroapi SAS - Asset Resilience Ratio
Euroapi SAS (EAPI) has an Asset Resilience Ratio of 9.16% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EAPI current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Euroapi SAS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Euroapi SAS's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Euroapi SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Euroapi SAS (EAPI) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €113.80 Million | 8.72% |
| Short-term Investments | €5.70 Million | 0.44% |
| Total Liquid Assets | €119.50 Million | 9.16% |
Asset Resilience Insights
- Limited Liquidity: Euroapi SAS maintains only 9.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Euroapi SAS Industry Peers by Asset Resilience Ratio
Compare Euroapi SAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Piramal Pharma Limited
NSE:PPLPHARMA |
Drug Manufacturers - Specialty & Generic | 0.73% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Euroapi SAS (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Euroapi SAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.16% | €119.50 Million ≈ $139.71 Million |
€1.30 Billion ≈ $1.53 Billion |
+3.84pp |
| 2024-12-31 | 5.32% | €79.20 Million ≈ $92.59 Million |
€1.49 Billion ≈ $1.74 Billion |
+2.66pp |
| 2023-12-31 | 2.66% | €42.90 Million ≈ $50.15 Million |
€1.61 Billion ≈ $1.89 Billion |
-1.91pp |
| 2022-12-31 | 4.57% | €79.30 Million ≈ $92.71 Million |
€1.74 Billion ≈ $2.03 Billion |
+2.76pp |
| 2021-12-31 | 1.81% | €29.30 Million ≈ $34.25 Million |
€1.62 Billion ≈ $1.89 Billion |
-7.80pp |
| 2020-12-31 | 9.61% | €153.90 Million ≈ $179.93 Million |
€1.60 Billion ≈ $1.87 Billion |
+1.18pp |
| 2019-12-31 | 8.44% | €133.00 Million ≈ $155.49 Million |
€1.58 Billion ≈ $1.84 Billion |
-- |
About Euroapi SAS
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; … Read more